NeoGenomics (NEO) remains unprofitable, with no signs of a turnaround in profitability expected within the next three years. Over the past five years, losses have accelerated at a rate of 30% per year. Revenue is forecast to grow at just 8.7% annually, which lags behind the broader US market's 10.2% pace. Margins continue to trend poorly, and net profit margins are firmly in negative territory. This paints a challenging performance picture for investors.

See our full analysis for NeoGenomics.

Next, we will see how these results match up with the widely followed market narratives and where the numbers push back on consensus thinking.

Sales Multiple Sits Above Industry Average

• NeoGenomics trades at a Price-To-Sales (P/S) ratio of 1.9x, higher than the US Healthcare industry average of 1.3x, yet below the peer group average of 2.6x.
• The analysts' consensus view suggests this higher multiple puts added pressure on the company to deliver future revenue growth and margin expansion.
  • Unlike peers with higher sales multiples, NeoGenomics has not yet achieved profitability. Its annual revenue growth of 8.7% is below the 10.2% US market average, raising questions about whether the current P/S ratio is justified.
  • Analysts highlight that to meet consensus valuation, NeoGenomics would need to grow its revenues to $893.1 million and reach earnings of $48.1 million by 2028. This goal depends on consistent operational execution.
• See if analysts’ predictions line up with the story in the data and what the market is saying next quarter. 📊 Read the full NeoGenomics Consensus Narrative.

Margin Pressures Remain Unresolved

• Net profit margins have stayed in negative territory, and no turnaround is expected within the next three years.
• The analysts' consensus view points to several challenges making margin expansion difficult:
  • Margin growth continues to be threatened by high fixed costs and declining nonclinical revenues. The latter has dropped in the double digits, making overall profitability harder to achieve than forecast.
  • Analysts also identify risks from delayed product launches and ongoing litigation, which could increase costs and limit the company's ability to close the gap with the industry-average margins of 5.4%.

Growth Forecast Lags Market Pace

• NeoGenomics is forecast to grow revenue at 8.7% per year, slower than the US market’s 10.2% pace, according to analysts.
• The analysts' consensus view indicates that while launches of new tests and investments in digital tools could provide some upside, significant risks remain:
  • Ongoing competitive pressure in oncology diagnostics and the need for successful new product rollouts leave management with little margin for error. Competitors expanding their portfolios could further erode NeoGenomics’ market share.
  • Unpredictable demand from pharma and biotech customers, due to funding uncertainty and changing drug development timelines, creates a risk for dependable revenue growth in the near term.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for NeoGenomics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Got a unique take on the data? Share your viewpoint and build a fresh narrative in just a few minutes. Do it your way

A great starting point for your NeoGenomics research is our analysis highlighting 1 important warning sign that could impact your investment decision.

See What Else Is Out There

NeoGenomics faces ongoing losses, shrinking margins, and subpar growth that trails both industry peers and the broader market.

For investors seeking companies with steadier financial performance and less earnings volatility, use our stable growth stocks screener (2122 results) to discover businesses that consistently deliver reliable growth and profitability across cycles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.